HomeCompareRGLS vs PEP

RGLS vs PEP: Dividend Comparison 2026

RGLS yields 24.51% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PEP wins by $48.8K in total portfolio value· pulled ahead in Year 10
10 years
RGLS
RGLS
● Live price
24.51%
Share price
$8.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.9K
Annual income
$10,627.09
Full RGLS calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — RGLS vs PEP

📍 PEP pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGLSPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGLS + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGLS pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGLS
Annual income on $10K today (after 15% tax)
$2,083.33/yr
After 10yr DRIP, annual income (after tax)
$9,033.03/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, PEP beats the other by $44,882.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGLS + PEP for your $10,000?

RGLS: 50%PEP: 50%
100% PEP50/50100% RGLS
Portfolio after 10yr
$120.3K
Annual income
$37,028.80/yr
Blended yield
30.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

RGLS
Analyst Ratings
9
Buy
9
Hold
Consensus: Buy
Price Target
$7.00
-14.2% upside vs current
Range: $7.00 — $7.00
Altman Z
46.8
Piotroski
1/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGLS buys
0
PEP buys
0
No recent congressional trades found for RGLS or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGLSPEP
Forward yield24.51%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$95.9K$144.7K
Annual income after 10y$10,627.09$63,430.49
Total dividends collected$60.2K$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$7.00$172.43

Year-by-year: RGLS vs PEP ($10,000, DRIP)

YearRGLS PortfolioRGLS Income/yrPEP PortfolioPEP Income/yrGap
1$13,151$2,450.98$10,854$514.44+$2.3KRGLS
2$17,084$3,012.41$11,982$758.21+$5.1KRGLS
3$21,937$3,657.30$13,526$1,136.44+$8.4KRGLS
4$27,862$4,389.03$15,727$1,741.93+$12.1KRGLS
5$35,022$5,209.71$19,012$2,750.28+$16.0KRGLS
6$43,593$6,120.11$24,173$4,514.44+$19.4KRGLS
7$53,765$7,119.64$32,789$7,793.80+$21.0KRGLS
8$65,734$8,206.35$48,258$14,354.51+$17.5KRGLS
9$79,713$9,376.98$78,586$28,686.63+$1.1KRGLS
10← crossover$95,920$10,627.09$144,688$63,430.49$48.8KPEP

RGLS vs PEP: Complete Analysis 2026

RGLSStock

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Full RGLS Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this RGLS vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGLS vs SCHDRGLS vs JEPIRGLS vs ORGLS vs KORGLS vs MAINRGLS vs MORGLS vs PMRGLS vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.